Relaxin Measurement in Different Endometrial Preparation Approaches for Frozen Embryo Transfer
NCT ID: NCT06526520
Last Updated: 2025-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
5 participants
OBSERVATIONAL
2024-08-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles
NCT04758871
Predictive Value of Mid-luteal Serum Progesterone Levels in Egg Donation Cycles
NCT02696694
Examination of Serum Progesterone Levels in an IVF Population Following Two Types of Egg Aspiration
NCT01513954
Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone
NCT06870266
Endometrial Preparation in Frozen Embryo Transfer Cycles
NCT03540979
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
These conditions are attributed to the absence of a CL in the HRT approach. Lately a new endometrial preparation approach is discussed and performed, the so called natural proliferative phase protocol, in which the follicle growth is monitored and when the lining is deemed to have a sufficient thickness and the triple lining pattern, exogeneous progesterone is started to induce secretory transformation before spontaneous ovulation. Despite some studies showing, that exogeneous progesterone administration might induce ovulation, it is not clear whether there will be a CL, producing Relaxin, in the NPP approach.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Natural cycle
Monitoring of a natural cycle
No interventions assigned to this group
natural proliferative phase cycle
Monitoring of a natural proliferative phase cycle
Exposure to progesterone or HRT medication
to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol
Hormonal replacement cycle
Monitoring of a hormonal replacement cycle
Exposure to progesterone or HRT medication
to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exposure to progesterone or HRT medication
to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Intake of any hormones within 3 months of study start
* desire to become pregnant
18 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ART Fertility Clinics LLC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barbara Lawrenz, PhD
Role: PRINCIPAL_INVESTIGATOR
ART Fertility Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ART Fertiltiy Clinic
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2406-ABU-007-BL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.